Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cannabinoid Oral Care + antimicrobial is a preclinical-stage cannabinoid-based oral care composition developed by APIRx Pharmaceutical USA (subsequently acquired by Incannex Healthcare). The product is formulated for oral administration and is specifically intended to address oral infections and other antimicrobial applications. It utilizes cannabinoids as the active therapeutic ingredients, leveraging APIRx's proprietary technology for the sustained oral mucosal delivery of cannabinoid formulations. While the specific cannabinoid profile and secondary antimicrobial agents (if any) have not been publicly detailed, the candidate is designed to provide localized treatment within the oral cavity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cannabinoid Oral Care + antimicrobial.